Αρχική World News Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory... World News Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy Από Ogkologos - 19 Φεβρουαρίου, 2026 322 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Transforming Cancer Clinical Trials for Better, Faster Results 14 Απριλίου, 2023 Get to Know CaringBridge 3 Ιουνίου, 2021 GreaterGood Is Helping UMN Fight Social Injustice with Scholarship for Underrepresented... 2 Φεβρουαρίου, 2021 Oncology Dietitians Don’t Usually Inquire About Food Insecurity in Cancer Patients,... 12 Φεβρουαρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS Cancer Rehabilitation Starts at Diagnosis 3rd Grader Writes Note for Teacher Battling Breast Cancer to Read... New drug available for rare thyroid cancer on NHS in England ESMO Gastrointestinal Cancers Congress 2024 Munich, Germany, 26-29 June